In vitro diagnostics (IVD) refers to the technique wherein the biological samples such as stool, tissues, blood, urine, and other body fluids are examined with the help of various medical devices and reagents. These body fluids are generally taken from the human body to detect infections and diseases. IVD tests are generally performed in hospital based laboratories, stand-alone laboratories, and point-of-care centres for the examination of diseases conditions. Various technologies used for test sample preparation include microarray techniques, polymerase chain reaction, mass spectrometry, and sequencing technologies. The France IVD market accounted for $2,943 million in 2016, and is estimated to reach $4,509 million by 2023, growing at a CAGR of 6.2% during the analysis period of (2017-2023) IVD market.
The market is segmented on the basis of product type, techniques, application, and end user. By product type, the market is categorized into reagents, instruments, and software & services. On the basis of technique, it is categorized into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry, and other IVD techniques. Application segment covered in the study includes infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and other indications. Based on end user it is classified into hospitals, academic and medical schools, point of care testing, and others.
KEY BENEFITS FOR STAKEHOLDERS
Comprehensive analysis of factors that drive and restrict the growth of the France IVD market is provided.
The projections in the market are made by studying the current and future market trends for the period (2016-2023) in terms of value.
Extensive analysis by technology and application helps understand the various trends and prevailing opportunities in the respective market
Key market players are profiled and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product Type
Reagents
Instruments
Software and Services
By Techniques
Immunodiagnostics
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassays (CLIAS)
Fluorescence Immunoassays (FIAS)
Colorimetric Immunoassays (CIS)
Rapid Tests
Enzyme-Linked Immunospot Assays (ELISPOT)
Radioimmunoassay
Western Blot
Blood Testing
Molecular Diagnostics
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Hybridization
DNA Diagnostics
Microarrays
Others
Tissue Diagnostics
Clinical Chemistry
Basic Metabolic Panel
Liver Panel
Lipid Profile
Thyroid Function Panel
Renal Profile
Electrolyte Panel
Specialty Chemicals
Other IVD Techniques
By Application
Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Other Indications
By End Users
Standalone Laboratory
Hospitals
Academic and Medical Schools
Point of Care Testing
Others
Others
List of players profiled in the report
Thermo Fisher Scientific Inc.
Alere Inc.
Biomerieux
Danaher Corporation
F. Hoffmann-La Roche AG
Becton Dickinson and Company
Bio-Rad Laboratories
Bayer AG
Sysmex Corporation
Johnson & Johnson
